Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.


TSX:BCT - Post by User

Post by LondonInveston Mar 22, 2022 10:20am
144 Views
Post# 34534188

Likely Trend Up For Break Away Gap

Likely Trend Up For Break Away Gap
This is just speculation, but the chart action in BCTX is very encouraging going into the AACR on April 12, 2022.  I expect it to continue to rise into the $10-$11 range and build a higher base.  Strong clinical results from presentation on April 12 could set up a sharp move higher with a break-away gap up.  It would propel stock above all previous highs and resistance and lead to a spectacular rally.

This is all speculation of course, but I like the current steady trend up and expect it to continue for next 3 weeks to get us in that $10-$11 range. 

Break-away gaps for stocks on news that launch a stock above previous resistance are always spectacular.
<< Previous
Bullboard Posts
Next >>